Published in Hepatitis Weekly, October 4th, 2004
According to a study from Taiwan, "hepatitis C virus (HCV) is a serious global problem, and present therapeutics are inadequate to cure HCV infection. In the present study, various antiviral assays show that arsenic trioxide (As2 O3 ) at submicromolar concentrations is capable of inhibiting HCV replication."
"The 50% effective concentration (EC50 ) of As2 O3 required to inhibit HCV replication was 0.35 mcM when it was determined by a reporter-based HCV replication assay, and the EC50 was below 0.2 mcM when it was determined by...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.